Table 1 Demographics and clinical data.

From: T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management

 

At-risk

Evolving IA

MTX 1st tx

Remission

n

158

294

70

145

Age

52 (19–79)

50 (21–90)

56 (21–87)

57 (20–87)

Female (%)

117 (74%)

176 (60%)

49 (70%)

90 (62%)

Smoking*

   Current

Not collected

50 (28%)

20 (28%)

25 (19%)

   Never

67 (38%)

25 (36%)

56 (43%)

   Previous

59 (34%)

25 (36%)

50 (38%)

Symptom duration (m)

Na

7 (0–24)

7 (0–19)

42 (9–276)

ACPA (%)

158 (100%)

138 (55%)*

48 (68%)

90 (62%)

RF (%)

73%

121 (40%)*

42 (60%)

78 (54%)

TJC

Na

9 (0–28)

10 (0–28)

0 (0–8)

SJC

Na

5 (0–22)

5 (0–21)

0 (0–8)

CRP

Na

18 (<5–228)

10 (<5–118)

0 (<5–38)

DAS

Na

4.2 (3.2–8)

5.1 (1.8–7.5)

1.77 (0.96–2.6)

  1. Data are described as median (range) or number (percentage). ACPA anticitrullinated peptide antibody, RF rheumatoid factor, TJC/SJC tender/swollen joint count, CRP C-reactive protein, DAS disease activity score. Na not applicable, *missing data.
Back to article page